Risk of neuroblastoma, birth-related characteristics, congenital malformations and perinatal exposures: A pooled analysis of the ESCALE and ESTELLE French studies (SFCE)

International Journal of Cancer

Volumn 139, Issue 9, 2016, Pages 1936-1948

  Rios, Paula ^a,b   Bailey, Helen D ^a,b   Orsi, Laurent ^a,b   Lacour, Brigitte ^a,b,c   Valteau Couanet, Dominique ^d   Levy, Dominique ^e   Corradini, Nadège ^f   Leverger, Guy ^g   Defachelles, Anne Sophie ^h   Gambart, Marion ⁱ   Sirvent, Nicolas ^j   Thebaud, Estelle ^k   Ducassou, Stéphane ^l   Clavel, Jacqueline ^a,b  

^a PARIS DESCARTES UNIVERSITY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d Service D'Oncologie Pédiatrique   (France)

^e INSTITUT CURIE   (France)

^f CENTRE LÉON BÉRARD   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ HÔPITAL DES ENFANTS   (France)

^j HÔPITAL ARNAUD DE VILLENEUVE   (France)

^k Hopital Mere Enfant CHU de Nantes   (France)

^l HÔPITAL PELLEGRIN   (France)

more..

Author keywords

childhood cancer; congenital malformations; fetal growth; neuroblastoma; risk factors

Indexed keywords

FOLIC ACID; MINERAL; VITAMIN;

AGE; ARTICLE; BREAST FEEDING; CANCER RISK; CASE CONTROL STUDY; CHILD; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPOSURE; FEMALE; FOLIC ACID SUPPLEMENTATION; GENDER; GENE AMPLIFICATION; HUMAN; LARGE FOR GESTATIONAL AGE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINERAL SUPPLEMENTATION; MYCN ONCOGENE; NEUROBLASTOMA; ONCOGENE; PERINATAL EXPOSURE; POPULATION RESEARCH; PREPREGNANCY CARE; PRIORITY JOURNAL; SKELETON MALFORMATION; SMALL FOR DATE INFANT; SUPPLEMENTATION; TELEPHONE INTERVIEW; UNCONDITIONAL LOGISTIC REGRESSION; UROGENITAL TRACT MALFORMATION; VITAMIN SUPPLEMENTATION;

EID: 84983035802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30239     Document Type: Article

References (51)

1. INCa report. Les cancers en France. Edition 2013 [Internet]. 2014;Available from: http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Les-cancers-en-France-Edition-2013
2. Lacour B, Guyot-Goubin A, Guissou S, et al. Incidence of childhood cancer in France: National Children Cancer Registries, 2000-2004. Eur J Cancer Prev 2010;19:173–81.
3. Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol 2014;11:704–13.
4. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 2009;27:289–297.;:–.
5. Carlsen NL. Neuroblastomas presenting in the first year of life: epidemiological differences from those presenting at older ages. Cancer Detect Prev 1996;20:251–61.
6. Urayama KY, Von Behren J, Reynolds P. Birth characteristics and risk of neuroblastoma in young children. Am J Epidemiol 2006;165:486–95.
7. Bluhm E, McNeil DE, Cnattingius S, et al. Prenatal and perinatal risk factors for neuroblastoma. Int J Cancer 2008;123:2885–90.
8. Schleiermacher G, Janoueix-Lerosey I, Delattre O. Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249–61.
9. Hamrick SE, Olshan AF, Neglia JP, et al. Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Paediatr Perinat Epidemiol 2001;15:328–37.
10. Bjørge T, Engeland A, Tretli S, et al. Birth and parental characteristics and risk of neuroblastoma in a population-based Norwegian cohort study. Br J Cancer 2008;99:1165–9.
11. Parodi S, Merlo DF, Ranucci A, et al. Risk of neuroblastoma, maternal characteristics and perinatal exposures: The SETIL study. Cancer Epidemiol 2014;38:686–94.
12. Neglia JP, Smithson WA, Gunderson P, et al. Prenatal and perinatal risk factors for neuroblastoma. A case-control study. Cancer 1988;61:2202–6.
13. Buck GM, Michalek AM, Chen CJ, et al. Perinatal factors and risk of neuroblastoma. Paediatr Perinat Epidemiol 2001;15:47–53.
14. Johnson KJ, Puumala SE, Soler JT, et al. Perinatal characteristics and risk of neuroblastoma. Int J Cancer 2008;123:1166–72.
15. Chow EJ, Friedman DL, Mueller BA. Maternal and perinatal characteristics in relation to neuroblastoma. Cancer 2007;109:983–92.
16. Schüz J, Forman MR. Birthweight by gestational age and childhood cancer. Cancer Causes Control 2007;18:655–63.
17. McLaughlin CC, Baptiste MS, Schymura MJ, et al. Perinatal risk factors for neuroblastoma. Cancer Causes Control 2009;20:289–301.
18. Johnson CC, Spitz MR. Neuroblastoma: case-control analysis of birth characteristics. J Natl Cancer Inst 1985;74:789–92.
19. Menegaux F, Olshan AF, Reitnauer PJ, et al. Positive association between congenital anomalies and risk of neuroblastoma. Pediatr Blood Cancer 2005;45:649–55.
20. French A. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther 2003;74:288–94.
21. Olshan AF, Smith JC, Bondy ML, et al. Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology 2002;13:575–580.
22. Goh YI, Bollano E, Einarson TR, et al. Prenatal multivitamin supplementation and rates of pediatric cancers: a meta-analysis. Clin Pharmacol 38 Ther 2007;81:685–91.
23. Daniels JL, Olshan AF, Pollock BH, et al. Breast-feeding and neuroblastoma, USA and Canada. Cancer Causes Control 2002;13:401–5.
24. Menegaux F, Olshan AF, Neglia JP, et al. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol 2004;159:843–51.
25. Munzer C, Menegaux F, Lacour B, et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: the ESCALE study (SFCE). Int J Cancer 2008;122:2315–21.
26. Amigou A, Rudant J, Orsi L, et al. Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE). Cancer Causes Control 2012;23:1265–77.
27. Orsi L, Rudant J, Ajrouche R, et al. Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy, and childhood acute leukemia: the ESTELLE study. Cancer Causes Control 2015;26:1003–17.
28. Blondel B, Kermarrec M. Les naissances en 2010 et leur évolution en 2003. 2012 [cited 2015 Jun 14];Available at: http://www.epsilon.insee.fr/jspui/handle/1/14305
29. Association des Utilisateurs de Dossiers Informatisés en Pédiatrie, Obstetrique et Gynécologie (AUDIPOG). Morphométrie néonatale. Poids, taille et périmètre crânien à la naissance. 2008;
30. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) [Internet]. 2015;Available at: http://www.who.int/classifications/icd/en/
31. EUROCAT- European Surveillance of congenital anomalies. Eurocat Guide 1.4 and Reference Documents [Internet]. 2013 [cited 2016 Feb 2];Available at: www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4
32. Harder T, Plagemann A, Harder A. Birth weight and risk of neuroblastoma: a meta-analysis. Int J Epidemiol 2010;39:746–56.
33. O'Neill KA, Murphy MF, Bunch KJ, et al. Infant birthweight and risk of childhood cancer: international population-based case control studies of 40 000 cases. Int J Epidemiol 2015;44:153–68.
34. Rahman N. Mechanisms predisposing to childhood overgrowth and cancer. Curr Opin Genet Dev 2005;15:227–33.
35. Callan AC, Milne E. Involvement of the IGF system in fetal growth and childhood cancer: an overview of potential mechanisms. Cancer Causes Control 2009;20:1783–98.
36. Foulkes WD, Buu PN, Filiatrault D, et al. Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montréal. Med Pediatr Oncol 1997;29:272–9.
37. Narod SA, Hawkins MM, Robertson CM, et al. Congenital anomalies and childhood cancer in Great Britain. Am J Hum Genet 1997;60:474–85.
38. Martin RM, Gunnell D, Owen CG, et al. Breast-feeding and childhood cancer: a systematic review with metaanalysis. Int J Cancer 2005;117:1020–31.
39. Smulevich VB, Solionova LG, Belyakova SV. Parental occupation and other factors and cancer risk in children. I. Study methodology and non-occupational factors. Int J Cancer 1999;83:712–7.
40. Hardell L, Dreifaldt AC. Breast-feeding duration and the risk of malignant diseases in childhood in Sweden. Eur J Clin Nutr 2001;55:179–85.
41. Greaves MF. Aetiology of acute leukaemia. Lancet 1997;349:344–9.
42. Alsaweed M, Lai CT, Hartmann PE, et al. Human milk miRNAs primarily originate from the mammary gland resulting in unique miRNA profiles of fractionated milk. Sci Rep 2016;6:20680
43. Michalek AM, Buck GM, Nasca PC, et al. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 1996;143:996–1001.
44. Mortensen JHS, Øyen N, Fomina T, et al. Supplemental folic acid in pregnancy and childhood cancer risk. Br J Cancer 2016;114:71–5.
45. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, et al. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Libr [Internet] 2010; cited 2015 Jun 4];Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007950.pub2/full
46. Marshall GM, Carter DR, Cheung BB, et al. The prenatal origins of cancer. Nat Rev Cancer 2014;14:277–89.
47. Tort J, Lelong N, Prunet C, et al. Maternal and health care determinants of preconceptional use of folic acid supplementation in France: results from the 2010 National Perinatal Survey. 2013;1661–7.
48. Williams CL, Bunch KJ, Stiller CA, et al. Cancer risk among children born after assisted conception. N Engl J Med 2013;369:1819–27.
49. Hargreave M, Jensen A, Nielsen TSS, et al. Maternal use of fertility drugs and risk of cancer in children—a nationwide population-based cohort study in Denmark. Int J Cancer 2015;136:1931–9.
50. Hargreave M, Jensen A, Toender A, et al. Fertility treatment and childhood cancer risk: a systematic meta-analysis. Fertil Steril 2013;100:150–61.
51. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459–65.